Septerna (SEPN) Competitors $24.28 +0.88 (+3.76%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends SEPN vs. OGN, PTCT, VRNA, RYTM, MLTX, JANX, XENE, EWTX, MRUS, and ACADShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Organon & Co. (OGN), PTC Therapeutics (PTCT), Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), Merus (MRUS), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Organon & Co. PTC Therapeutics Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Xenon Pharmaceuticals Edgewise Therapeutics Merus ACADIA Pharmaceuticals Septerna (NASDAQ:SEPN) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking. Do analysts rate SEPN or OGN? Septerna currently has a consensus target price of $43.67, indicating a potential upside of 79.85%. Organon & Co. has a consensus target price of $21.33, indicating a potential upside of 46.32%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Organon & Co. 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, SEPN or OGN? Organon & Co. has higher revenue and earnings than Septerna. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$981K1,098.99N/AN/AN/AOrganon & Co.$6.41B0.59$1.02B$5.042.89 Do institutionals & insiders have more ownership in SEPN or OGN? 77.4% of Organon & Co. shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is SEPN or OGN more profitable? Organon & Co. has a net margin of 20.30% compared to Septerna's net margin of 0.00%. Organon & Co.'s return on equity of 644.70% beat Septerna's return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Organon & Co. 20.30%644.70%8.12% Does the media refer more to SEPN or OGN? In the previous week, Organon & Co. had 2 more articles in the media than Septerna. MarketBeat recorded 5 mentions for Organon & Co. and 3 mentions for Septerna. Organon & Co.'s average media sentiment score of 0.42 beat Septerna's score of 0.22 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer SEPN or OGN? Organon & Co. received 13 more outperform votes than Septerna when rated by MarketBeat users. However, 100.00% of users gave Septerna an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes4100.00% Underperform VotesNo VotesOrganon & Co.Outperform Votes1734.00% Underperform Votes3366.00% SummaryOrganon & Co. beats Septerna on 10 of the 15 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08B$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.88%4.21%P/E RatioN/A10.5090.8317.14Price / Sales1,098.99195.361,112.01116.85Price / CashN/A57.1642.0237.88Price / BookN/A5.104.774.78Net IncomeN/A$151.51M$119.70M$225.60M7 Day Performance8.44%-2.11%-1.86%-1.23%1 Month Performance11.43%-3.11%11.45%3.07%1 Year PerformanceN/A11.53%30.43%16.48% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna2.2229 of 5 stars$24.28+3.8%$43.67+79.8%N/A$1.08B$981,000.000.00N/AHigh Trading VolumeOGNOrganon & Co.4.8031 of 5 stars$14.58-4.7%$21.33+46.3%+10.9%$3.75B$6.26B2.9110,000PTCTPTC Therapeutics3.6544 of 5 stars$48.61+4.8%$54.08+11.2%+71.0%$3.75B$900.66M-8.151,410Analyst DowngradePositive NewsVRNAVerona Pharma0.7085 of 5 stars$42.68+3.0%$43.83+2.7%+153.4%$3.47B$460,000.00-22.2730RYTMRhythm Pharmaceuticals4.1088 of 5 stars$55.25+0.0%$63.70+15.3%+25.1%$3.40B$77.43M-12.76140Analyst ForecastNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.6288 of 5 stars$52.98+3.2%$79.88+50.8%-9.3%$3.39BN/A-40.842JANXJanux Therapeutics3.6249 of 5 stars$61.56+0.7%$89.90+46.0%+496.3%$3.23B$13.05M-52.2330Positive NewsXENEXenon Pharmaceuticals2.8037 of 5 stars$41.31+3.1%$56.90+37.7%-5.8%$3.15B$9.43M-14.20251Insider TradeEWTXEdgewise Therapeutics2.7304 of 5 stars$32.69+18.4%$42.33+29.5%+261.7%$3.10BN/A-22.8560Analyst ForecastAnalyst RevisionHigh Trading VolumeMRUSMerus2.8134 of 5 stars$42.80-0.1%$85.64+100.1%+61.7%$2.93B$35.93M-10.8437ACADACADIA Pharmaceuticals3.8511 of 5 stars$17.34+0.5%$25.60+47.6%-41.9%$2.89B$726.44M22.13510 Related Companies and Tools Related Companies OGN Competitors PTCT Competitors VRNA Competitors RYTM Competitors MLTX Competitors JANX Competitors XENE Competitors EWTX Competitors MRUS Competitors ACAD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEPN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
